RT Journal Article
SR Electronic
T1 How To Minimize Toxic Exposure to Pyridine during Continuous Infusion of Ceftazidime in Patients with Cystic Fibrosis?
JF Antimicrobial Agents and Chemotherapy
JO Antimicrob. Agents Chemother.
FD American Society for Microbiology
SP 2849
OP 2855
DO 10.1128/AAC.02637-13
VO 58
IS 5
A1 Bourget, P.
A1 Amin, A.
A1 Dupont, C.
A1 Abely, M.
A1 Desmazes-Dufeu, N.
A1 Dubus, J. C.
A1 Jouani, B.-L.
A1 Merlette, C.
A1 Nové-Josserand, R.
A1 Pages, J.
A1 Panzo, R.
A1 Vidal, F.
A1 Voge, F.
A1 Hubert, D.
YR 2014
UL http://aac.asm.org/content/58/5/2849.abstract
AB Ceftazidime is particularly efficient against Pseudomonas aeruginosa in cystic fibrosis patients. Thus, the spontaneous production of pyridine, which is a toxic product, raises some concern. Our aim was to examine the kinetics of degradation of ceftazidime in portable infusion pumps either at 4°C, 22°C, or 33°C and to propose some recommendations in order to reduce the pyridine exposure. Two administration models were studied in vitro. In model 1, we administered 12 g of ceftazidime infused over 23 h (once-daily infusion) compared to 6 g infused over 11.5 h in model 2 (twice-daily regimen). Samples were collected at 0 h and then every 4 and 2 h after the shaping of portable infusion pumps in models 1 and 2, respectively. Both ceftazidime and pyridine were analyzed using an ultraviolet high-performance liquid chromatograph. Production of pyridine is highly depending on the temperature. The in situ production of pyridine per day of treatment decreases at a ratio close to 1/6 and 1/3 between 33°C and 4°C in models 1 and 2, respectively. Regardless of the conditions, the production of pyridine is significantly lower in model 2, whereas the total delivery amount of ceftazidime is significantly higher at 4°C and 33°C compared to that in model 1. According to a the precautionary principle, these findings lead to three major recommendations: (i) exposing a solution of ceftazidime to over 22°C should be strictly avoided, (ii) a divided dose of 6 g over 11.5 h instead of a once-daily administration is preferred, and (iii) infusion should be administered immediately after reconstitution.